Clinical Trial Update: DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension [Phase 3]

View source ↗

Summary

Update on the long-term safety extension of the Darusentan Phase 3 DORADO study (DORADO-EX/DAR-311) in resistant hypertension, noting termination of the extensi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Darusentan (darusentan)

Snippet

Sponsor: Gilead Sciences | Conditions: Hypertension | Phase 3 | Status: TERMINATED